MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitiv... MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. It is developing MIRA1a, a synthetic cannabinoid analog to treat anxiety and chronic pain by targeting the cannabinoid type 1 and type 2 receptors. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Baltimore, Maryland. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.08 | -5.22875816993 | 1.53 | 1.7499 | 1.38 | 543797 | 1.60875871 | CS |
4 | 0.3 | 26.0869565217 | 1.15 | 2.5591 | 1.04 | 3493843 | 1.74922683 | CS |
12 | -1.19 | -45.0757575758 | 2.64 | 2.7 | 1.02 | 2038099 | 1.76996715 | CS |
26 | 0.7319 | 101.92173792 | 0.7181 | 5.01 | 0.51 | 3396036 | 3.0498378 | CS |
52 | -2.45 | -62.8205128205 | 3.9 | 6.4 | 0.51 | 1937030 | 2.89777753 | CS |
156 | -5.55 | -79.2857142857 | 7 | 7.9799 | 0.51 | 1509996 | 2.92471487 | CS |
260 | -5.55 | -79.2857142857 | 7 | 7.9799 | 0.51 | 1509996 | 2.92471487 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.